Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.

@article{Furuse1999PhaseIS,
  title={Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.},
  author={Kiyoyuki Furuse and Masahiro Fukuoka and Masaaki Kawahara and Hidefumi Nishikawa and Yoshiki Takada and Shinzoh Kudoh and Nobuyuki Katagami and Yutaka Ariyoshi},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={1999},
  volume={17 9},
  pages={2692-9}
}
PURPOSE A phase III study was performed to determine whether concurrent or sequential treatment with radiotherapy (RT) and chemotherapy (CT) improves survival in unresectable stage III non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS Patients were assigned to the two treatment arms. In the concurrent arm, chemotherapy consisted of cisplatin (80 mg/m(2) on days 1 and 29), vindesine (3 mg/m(2) on days 1, 8, 29, and 36), and mitomycin (8 mg/m(2) on days 1 and 29). RT began on day 2 at a… CONTINUE READING
Highly Influential
This paper has highly influenced a number of papers. REVIEW HIGHLY INFLUENTIAL CITATIONS